Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
the ONA take:
Pancreatic cancer continues to have poor prognosis with a low 5-year survival rate. Many patients have advanced disease at diagnosis — either locally advanced pancreatic cancer (LAPC) or metastatic disease — with a median overall survival of less than 2 years.
First-line therapies such as gemcitabine monotherapy, FOLFIRINOX, and nab-paclitaxel plus gemcitabine are proven to increase survival. Most patients with advanced disease experience disease progression; however, those with good performance status may be candidates for second-line therapy.
Although studies on second-line therapies for pancreatic cancer are scarce, investigators are increasingly focusing on these treatments. This review discusses the published data on chemotherapy as second-line therapy for patients with advanced pancreatic cancer.
OncoTargets and Therapy
Abstract: Pancreatic cancer remains one of the most lethal malignant diseases worldwide. The majority of patients present with advanced disease and, therefore, need palliative chemotherapy. Some chemotherapeutic regimens have been well established as first-line therapies and have been shown to increase survival; however, almost all patients with advanced pancreatic cancer will experience disease progression after first-line therapy. Nevertheless, many patients who retain good performance status after initial treatment remain good candidates for additional therapy. Historically, few studies have assessed second-line therapy, with most reports representing small phase II trials with variable findings; however, clinical research for second-line treatment has increased in the past decade, and several randomized controlled trials using different regimens have been published. The current literature shows varying results on treatment efficacy and tolerability. Thus, we reviewed the published data on the use of chemotherapy in the second-line setting for the treatment of advanced pancreatic cancer.
Keywords: pancreatic cancer, second-line, chemotherapy, targeted therapy
Pancreatic cancer is a highly lethal disease, for which the 5-year relative survival rate is approximately 7%–8%.1,2 It remains the fourth leading cause of cancer-related deaths, with approximately 43,090 deaths estimated in the US in 2017.3 Most patients (approximately 80%) are ineligible for potential curative resection at diagnosis.4 In these cases, pancreatic cancer is diagnosed at an advanced stage – either as locally advanced pancreatic cancer (LAPC) or as metastatic disease – with a median overall survival (OS) of 9–15 and 6–9 months, respectively.5 Gemcitabine has been the standard first-line treatment in this advanced setting for over a decade.6 However, since 2011, new chemotherapeutic regimens (FOLFIRINOX and nab-paclitaxel plus gemcitabine) have shown improved survival benefit over gemcitabine monotherapy and are the most commonly administered first-line therapies in patients with good performance status.7,8 Therefore, gemcitabine monotherapy is now more frequently used as an option for patients with advanced pancreatic cancer who have poor performance status. Nonetheless, almost all patients will inevitably experience disease progression during or following first-line therapy and, beyond first-line treatment, approximately half of all patients with advanced pancreatic cancer remain in good general condition and, therefore, may receive subsequent therapies.9
Historically, multiple phase II studies have used various single agents or combination regimens in the second-line setting to improve survival, although most of these attempts have been in vain. However, in recent years, second-line chemotherapies have been developed using different regimens as standards. Several randomized phase III trials, including NAPOLI-1, CONKO-003, and PANCREOX, have shown promising results in improving survival, thus representing potential second-line options for patients with gemcitabine-resistant pancreatic cancer.10–12 However, reflecting the contradictory results on treatment efficacy and tolerability and criticisms on selective enrollment and study biases, the optimal second-line strategy for pancreatic cancer remains unknown.
In this review, we summarize current second-line chemotherapy options, second-line targeted therapies, and the most promising second-line agents to highlight state-of-the-art and future directions of second-line treatment in advanced pancreatic cancer.